Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients

Theodor Bilharz Research Institute

Bibliographic Information

Authors: El-Khayat H.; Kamal E.M.; Yakoot M.; Gawad M.A.; Kamal N.; El Shabrawi M.; Sameh Y.; Haseeb A.; Fouad Y.; Attia D.

Journal: European Journal of Gastroenterology and Hepatology

Publisher: Lippincott Williams and Wilkins

Publication Date: August 2019

Volume / Issue: Volume 31 / Issue 8

Pages: 1004–1009

ISSN: 0954691X

DOI: 10.1097/MEG.0000000000001360

Scopus: View on Scopus

PubMed: 30676473

Document Type: Article


Authors and Affiliations

El-Khayat H., Department of Gastroenterology Hepatology and Endemic Medicine, Theodore Bilharz Research Institute, Egypt; Kamal E.M., Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University Hospitals, Minia, Egypt; Yakoot M., Green Clinic Research Centre, Alexandria, Egypt; Gawad M.A., Pediatrics and Pediatrics Hepatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Kamal N., Pediatric and Pediatrics Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; El Shabrawi M., Pediatric and Pediatrics Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Sameh Y., Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Haseeb A., Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Fouad Y., Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University Hospitals, Minia, Egypt; Attia D., Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt


Abstract

BackgroundThe sustained virological response (SVR) rate for the 12-week sofosbuvir (SOF)/ledipasvir (LVD) treatment of adolescent genotype-4 patients is high. The aim of this study is to evaluate 8 versus 12-week treatment efficacy and safety in adolescent genotype-4 patients.Patients and methodsIn total, 157 chronic hepatitis C-infected adolescent patients (mean age 14±2 years, 62% males) were included in this study. All patients received a morning dose of SOF (400 mg)/LVD (90 mg) as a single tablet for 8 and 12 weeks. Laboratory and biochemical monitoring were performed at weeks 4 and 8, end of treatment (8/12) and 12 weeks after the end of treatment (SVR12).ResultsIn total, SVR12 was 98% [95% confidence interval (CI): 96-100] for all treated patients. For patients treated for 12 weeks, SVR12 was 97.6% (95% CI: 96-101) (82/84 patients), and 98.6% (95% CI: 93-101) (72/73) patients for those treated for 8 weeks. For both regimens, no serious adverse effects, treatment discontinuation or cases of death were detected. The main adverse effects for the 8-week patient group were fatigue (2.8%), headache (1.4%), nausea (1.4%) and epigastric tenderness (1.4%). For the 12-week-treated group, adverse events were epigastric tenderness (1.2%), nausea (1.2%), diarrhoea (2.4%) and rash (2.4%). Three patients were lost to follow-up: Two were in the 12-week treatment group and one was in the 8-week group. All of them reached end of treatment but were lost before SVR12. No relapsers were observed in either group.ConclusionEight weeks of treatment of SOF/LVD combination is equally effective and safe as 12 weeks in adolescent genotype-4 patients. © 2019 Lippincott Williams and Wilkins. All rights reserved.


Keywords

12-17 years old; direct-acting antivirals; GT-4; hepatitis C virus; SVR12; Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Elasticity Imaging Techniques; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver; Male; Prospective Studies; Treatment Outcome; Uridine Monophosphate; ledipasvir plus sofosbuvir; antivirus agent; benzimidazole derivative; fluorene derivative; ledipasvir, sofosbuvir drug combination; uridine phosphate; abdominal tenderness; antiviral therapy; Article; chronic hepatitis C; clinical effectiveness; cross-sectional study; drug safety; drug withdrawal; fatigue; follow up; headache; human; major clinical study; morning dosage; nausea; priority journal; prospective study; treatment duration; diagnostic imaging; dose response; drug administration; elastography; oral drug administration; procedures


Citation Information

Scopus Citations: 17


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects